Feru-guard and General Antioxidant Capacity in Older People

September 2, 2026 updated by: Lynne Shinto, ND, MPH, Oregon Health and Science University

Feru-guard (Ferulic Acid and Angelica Archangelica Extract) and General Antioxidant Capacity in Older People

To determine if Feru-guard, a dietary supplement, can decrease general oxidation and inflammation in people who are ages 65-89 years old. Also to determine if Feru-guard is safe in older people when given for 3 months.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Lynne Shinto, ND, MPH
  • Phone Number: (503) 494-5035
  • Email: shintol@ohsu.edu

Study Locations

  • United States
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 65 to 89 years old
  • Not demented or mild cognitive impairment, defined as Clinical Dementia Rating (CDR) =0 and MMSE >24.
  • Informant has direct contact with participant at least 2 days per week to verify functional status, CDR, and accompany participant to in-clinic screening visit
  • Sufficient English language skills to complete all testing.

Exclusion Criteria:

  • Any dementing illness (AD, vascular dementia, normal pressure hydrocephalus, or Parkinson's disease); dementia defined by CDR ≥ 0.50, MMSE < 25
  • AD medication (e.g. acetylcholinesterase inhibitors, NMDA receptor agonist, disease-modifying monoclonal antibody immunotherapy (e.g. lecanemab))
  • Significant disease of the CNS such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis
  • Alcohol or substance abuse according to DSM-IV criteria within the last 2 years
  • Major depression, schizophrenia, or other major psychiatric disorder defined by DSM-IV criteria
  • Participants on blood thinners such as warfarin (Coumadin, jantoven), rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran (pradaxa), apixaban (eliquis) dalteparin (fragmin), enoxaparin (lovenox). Aspirin use is allowed.
  • Participants with malignancy or an acute inflammatory disease.
  • Participants with critical cardiovascular, circulatory, respiratory, kidney, or liver disease or diabetes
  • Illness that requires >1 visit /month to a clinician
  • BMI of >30
  • Cancer within the last 5 years, with the exception of localized prostate cancer (Gleason Grade < 3) and non-metastatic skin cancers (melanoma).

  • Medications:

    1. CNS active meds that have not been on stable doses for at least 2 months (cimetidine, beta-blockers, and SSRIs)
    2. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit
    3. Over the counter supplements are not by themselves exclusionary, however, subjects are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these agents are recorded
  • Participants who have taken Feru-guard, ferulic acid, or Angelica archangelica supplementation within the last year.
  • Enrollment in another clinical trial or treatment study within the previous 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Feru-guard
Feru-guard capsules
Dietary supplement: Feru-guard
Ferulic acid and Angelica dietary supplement in capsules
Placebo Comparator: Placebo Group
Placebo capsules that are matched in size, and color
Other: Placebo
Placebo capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anti-oxidant Measure
Time Frame: 12 Weeks
general oxidative stress marker malondialdehyde (MDA),
12 Weeks
general oxidative stress marker malondialdehyde (MDA),
Time Frame: 12 weeks
12 weeks
Anti-inflammatory measure
Time Frame: 12 weeks
an inflammatory marker tumor necrosis factor alpha (TNF-alpha).
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Events
Time Frame: 12 weeks
Adverse Event Report
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Oregon Health and Science University

Collaborators

Glovia Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

July 31, 2028

Study Registration Dates

First Submitted

August 31, 2026

First Submitted That Met QC Criteria

September 2, 2026

First Posted (Actual)

September 3, 2026

Study Record Updates

Last Update Posted (Actual)

September 3, 2026

Last Update Submitted That Met QC Criteria

September 2, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 17966

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe